Babies born to HIV-positive women who took Kaletra were no more likely to have birth defects than infants born to the general population, according to a U.S. study. Researchers said the prevalence of birth defects was 2.4% among women taking the drug, which contains the protease inhibitors lopinavir and ritonavir. Women who took the drug during their first trimester, however, were more likely to have a preterm birth or low-birth-weight baby.

Related Summaries